logo
Twitter
Discord
Email
logo
Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

NASDAQ•FATE
CEO: Dr. Bahram Valamehr M.B.A., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2013-10-01
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Contact Information
12278 Scripps Summit Drive, San Diego, CA, 92131, United States
858-875-1800
www.fatetherapeutics.com
Market Cap
$139.58M
P/E (TTM)
-0.9
37
Dividend Yield
--
52W High
$1.94
52W Low
$0.66
52W Range
43%
Rank62Top 92.6%
1.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$1.74M-43.36%
4-Quarter Trend

EPS

-$0.27-32.50%
4-Quarter Trend

FCF

-$26.58M-11.15%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Net Loss Significantly Reduced Nine-month net loss narrowed to $103.9 M from $134.1 M in 2024, driven by lower operating expenses across R&D and G&A.
Operating Cash Burn Improved Cash used in operating activities decreased to $82.8 M for nine months, reflecting better cost management post-restructuring efforts.
R&D Spending Lowered Research and development expenses totaled $82.4 M for nine months, down $19.0 M compared to the prior year period.
CIRM Funding Received Received $3.8 M from FT836 CIRM award and $5.1 M total from FT819 award, recorded as liabilities on balance sheet.

Risk Factors

Substantial Future Capital Required Anticipates continued operating losses requiring substantial additional funding to complete development and seek regulatory approval.
Novel Technology Uncertainty iPSC platform and gene-editing technologies face high technological uncertainty; development success is not assured.
Manufacturing Scale-Up Risks Complex manufacturing processes for cell therapies risk cost overruns, quality control issues, and potential regulatory delays.
Ongoing Legal Proceedings Currently defending against securities class action and derivative litigation, which could divert resources and incur costs.

Outlook

Focus on Clinical Development Plan to significantly invest in current R&D, including clinical trials, GMP production, and technology transfer activities.
Ono Funding Secured Committed funding from Ono collaboration continues through June 2026, supporting research and preclinical development efforts.
Extended Cash Runway August 2025 restructuring aims to reduce operating expenses and extend cash runway through the end of 2027.
Navigating Regulatory Landscape Will continue engaging regulatory authorities for development pathways, anticipating potential changes in requirements.

Peer Comparison

Revenue (TTM)

Innate Pharma S.A.IPHA
$36.93M
-61.2%
Tonix Pharmaceuticals Holding Corp.TNXP
$10.30M
-145.5%
Nkarta, Inc.NKTX
$9.03M
-14.3%

Gross Margin (Latest Quarter)

Applied Therapeutics, Inc.APLT
100.0%
+0.0pp
Fate Therapeutics, Inc.FATE
100.0%
+0.0pp
Tonix Pharmaceuticals Holding Corp.TNXP
58.5%
+13.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
FBRX$399.61M-11.0-75.6%0.0%
ACHV$298.11M-3.7-196.7%19.1%
TNXP$234.28M-1.6-55.2%0.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-2.2%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 4, 2026
|
EPS:-$0.27
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 13, 2025|
    Revenue: $1.74M-43.4%
    |
    EPS: $-0.27-32.5%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 12, 2025|
    Revenue: $1.91M-71.8%
    |
    EPS: $-0.29-12.1%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 13, 2025|
    Revenue: $1.63M-15.4%
    |
    EPS: $-0.32-31.9%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 5, 2025|
    Revenue: $13.63M-78.5%
    |
    EPS: $-1.64+0.0%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 12, 2024|
    Revenue: $3.07M+58.1%
    |
    EPS: $-0.40-13.0%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 13, 2024|
    Revenue: $6.77M+625.8%
    |
    EPS: $-0.33-38.9%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 9, 2024|
    Revenue: $1.93M-96.7%
    |
    EPS: $-0.47+402.7%
    Beat

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 26, 2024|
    Revenue: $63.53M-34.0%
    |
    EPS: $-1.64+43.6%
    Miss